Maxigen BiotechTPE:1783 +0.13%87 Market Cap is NT$3,502.0 Mil as of Jul. 01, 2026. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.07 (Significantly Undervalued). Among 868 Medical Devices & Instruments companies, Maxigen Biotech ranks worse than 50.81% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Maxigen Biotech's share price for the quarter that ended in Dec. 2025 was NT$42.8. Maxigen Biotech's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 89.7 Mil. Therefore, Maxigen Biotech's market cap for the quarter that ended in Dec. 2025 was NT$3,838.3 Mil.
Maxigen Biotech's quarterly market cap
increased
from Jun. 2025 (NT$3,838.3 Mil) to Sep. 2025 (NT$4,098.4 Mil) but then
declined
from Sep. 2025 (NT$4,098.4 Mil) to Dec. 2025 (NT$3,838.3 Mil).
Maxigen Biotech's annual market cap
increased
from Dec. 2023 (NT$4,304.4 Mil) to Dec. 2024 (NT$4,364.5 Mil) but then
declined
from Dec. 2024 (NT$4,364.5 Mil) to Dec. 2025 (NT$3,838.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Maxigen Biotech's Enterprise Value for Today is NT$2,725.7 Mil.
Maxigen Biotech (TPE:1783) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Maxigen Biotech Market Cap Related Terms
Maxigen Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Maxigen Biotech's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a Market Cap of NT$3,502.0 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Maxigen Biotech and its competitors. According to the industry distribution chart, Maxigen Biotech ranks #441 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 50.8%.
Is Maxigen Biotech's Market Cap too high?
Maxigen Biotech's current Market Cap is NT$3,502.0 Mil. Based on the distribution chart, Maxigen Biotech ranks #441 out of 868 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #441 out of 868 companies for Market Cap. This places Maxigen Biotech in the lower half of its industry. The industry median Market Cap is 118.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 118.46, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Maxigen Biotech and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 118.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Market Cap is NT$3,502.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.07, compared to a current price of NT$39.05 — trading 36.1% below its estimated fair value. The current Market Cap is NT$3,502.0 Mil. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Market Cap is NT$3,502.0 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$39.05 is trading 36.1% below its estimated GF Value™ of NT$61.07.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Market Cap: NT$3,502.0 Mil
GF Value™: NT$61.07 vs. price of NT$39.05 (36.1% below fair value)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
